title: Osteopontin in cardiovascular disease: a potential therapeutic target.
abstract: Osteopontin (OPN), also known as 44kDa bone phosphoprotein, sialoprotein I, secreted phosphoprotein I, 2ar, uropontin, and early T-lymphocyte activation-1 (Eta-1), is a multifunctional protein. OPN has been found to be expressed in various cell types and species with many physiologic and pathologic functions. OPN has emerged as a potential biomarker and mediator in cardiovascular disease. In this review, we will discuss the roles of OPN in cardiovascular disease, specifically in vascular and valvular heart disease, myocardial infarction and heart failure.
authors.affiliation: From the Division of Cardiology, Department of Medicine, New Jersey Medical School, Newark, NJ.
authors.forename: Alfonso H
authors.initials: AH
authors.lastname: Waller
authors.forename: Monica
authors.initials: M
authors.lastname: Sanchez-Ross
authors.forename: Edo
authors.initials: E
authors.lastname: Kaluski
authors.forename: Marc
authors.initials: M
authors.lastname: Klapholz
mesh_terms: D015415:Biomarkers; D002318:Cardiovascular Diseases / Q000503:physiopathology*; D006333:Heart Failure / Q000503:physiopathology; D006349:Heart Valve Diseases / Q000503:physiopathology; D006801:Humans; D009203:Myocardial Infarction / Q000503:physiopathology; D053495:Osteopontin / Q000502:physiology*
chemical_list: D015415:Biomarkers; D053495:Osteopontin